Business Description
Armata Pharmaceuticals Inc
NAICS : 325414
SIC : 2836
ISIN : US03211P3010
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.23 | |||||
Equity-to-Asset | -0.47 | |||||
Debt-to-Equity | -2.97 | |||||
Debt-to-EBITDA | -2.1 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -13.4 | |||||
3-Year EPS without NRI Growth Rate | -10.1 | |||||
3-Year FCF Growth Rate | -9.8 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 36.35 | |||||
9-Day RSI | 41.46 | |||||
14-Day RSI | 44.12 | |||||
6-1 Month Momentum % | -10.22 | |||||
12-1 Month Momentum % | 148.48 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.38 | |||||
Quick Ratio | 0.38 | |||||
Cash Ratio | 0.34 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -24.6 | |||||
Shareholder Yield % | -72.62 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROA % | -73.48 | |||||
ROIC % | -33.23 | |||||
ROC (Joel Greenblatt) % | -147.45 | |||||
ROCE % | -139.97 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | -2.73 | |||||
EV-to-Forward-EBIT | -4.86 | |||||
EV-to-EBITDA | -2.76 | |||||
EV-to-Forward-EBITDA | -4.86 | |||||
EV-to-Forward-Revenue | 46.15 | |||||
EV-to-FCF | -4.73 | |||||
Earnings Yield (Greenblatt) % | -36.63 | |||||
FCF Yield % | -51.19 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Armata Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -2.102 | ||
Beta | 2.84 | ||
Volatility % | 135.21 | ||
14-Day RSI | 44.12 | ||
14-Day ATR (€) | 0.131055 | ||
20-Day SMA (€) | 2.535 | ||
12-1 Month Momentum % | 148.48 | ||
52-Week Range (€) | 0.925 - 4.46 | ||
Shares Outstanding (Mil) | 36.15 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Armata Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Armata Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Armata Pharmaceuticals Inc Frequently Asked Questions
What is Armata Pharmaceuticals Inc(FRA:TG1N)'s stock price today?
When is next earnings date of Armata Pharmaceuticals Inc(FRA:TG1N)?
Does Armata Pharmaceuticals Inc(FRA:TG1N) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |